CN101856389A - Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof - Google Patents
Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof Download PDFInfo
- Publication number
- CN101856389A CN101856389A CN200910131887A CN200910131887A CN101856389A CN 101856389 A CN101856389 A CN 101856389A CN 200910131887 A CN200910131887 A CN 200910131887A CN 200910131887 A CN200910131887 A CN 200910131887A CN 101856389 A CN101856389 A CN 101856389A
- Authority
- CN
- China
- Prior art keywords
- cerebral
- blood
- acid
- chinese medicinal
- stasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 15
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims abstract description 29
- 239000008280 blood Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 241000218628 Ginkgo Species 0.000 claims abstract description 21
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 21
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 21
- -1 patches Substances 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 230000017531 blood circulation Effects 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 9
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 241000545744 Hirudinea Species 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
- 238000010521 absorption reaction Methods 0.000 claims abstract description 6
- 239000007901 soft capsule Substances 0.000 claims abstract description 6
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 5
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims abstract description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 5
- 206010008132 Cerebral thrombosis Diseases 0.000 claims abstract description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 5
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims abstract description 5
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims abstract description 5
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 239000007921 spray Substances 0.000 claims abstract description 5
- 239000000829 suppository Substances 0.000 claims abstract description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 4
- 206010053942 Cerebral haematoma Diseases 0.000 claims abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 4
- 206010020772 Hypertension Diseases 0.000 claims abstract description 4
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims abstract description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 4
- 230000001684 chronic effect Effects 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims abstract description 4
- 239000007924 injection Substances 0.000 claims abstract description 4
- 239000002502 liposome Substances 0.000 claims abstract description 4
- 239000000693 micelle Substances 0.000 claims abstract description 4
- 239000004005 microsphere Substances 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims abstract description 4
- 239000006188 syrup Substances 0.000 claims abstract description 4
- 235000020357 syrup Nutrition 0.000 claims abstract description 4
- 210000002385 vertebral artery Anatomy 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 30
- 239000009636 Huang Qi Substances 0.000 claims description 21
- 241000237903 Hirudo Species 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 7
- 239000003172 expectorant agent Substances 0.000 claims description 7
- 230000003419 expectorant effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000008344 brain blood flow Effects 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 208000002173 dizziness Diseases 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000021395 porridge Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 2
- KWKVAGQCDSHWFK-VNKDHWASSA-N Methyl sorbate Chemical compound COC(=O)\C=C\C=C\C KWKVAGQCDSHWFK-VNKDHWASSA-N 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 17
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 239000006187 pill Substances 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 230000000302 ischemic effect Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 2
- 241001072909 Salvia Species 0.000 abstract 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 210000004233 talus Anatomy 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000034657 Convalescence Diseases 0.000 abstract 1
- 239000004375 Dextrin Substances 0.000 abstract 1
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 235000019425 dextrin Nutrition 0.000 abstract 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- 239000000284 extract Substances 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 229940032147 starch Drugs 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 2
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000331777 Arisaema balansae Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241001279228 Campylotropis hirtella Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010023832 Florigen Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000237678 Hirudinidae Species 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000612122 Myrsine Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000001261 florigenic effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal preparation which is used for treating cardiovascular and cerebrovascular diseases and contains active ingredients of root of red-rooted salvia, astragalus, ginkgo leaf and leech and application thereof. The Chinese medicinal preparation of the invention comprises oral administration preparations and oral administration slow (controlled) release formulations thereof such as tablets, capsules, soft capsules, granules, syrups, micro-pills, microspheres, ointment, sublimed preparations, injection, suppositories, creams, sprays, patches, micelle, aqueous solution agents, liposome, dextrin inclusion compound and the like. The Chinese medicinal preparation which takes the root of red-rooted salvia, the astragalus, the ginkgo leaf and the leech as main active ingredients has the effects of invigorating blood circulation and dissolving stasis and promoting blood circulation and stopping pain, is suitable for preventing and treating meridians qi-deficiency and blood-stasis type cerebral infarction diseases, arteriosclerosis, coronary heart diseases, angina, acute myocardial infarction, ischemic cerebral apoplexy, cerebral thrombosis and sequelae thereof, high blood viscosity, hyperlipidemia, chronic hypertension, atherosclerosis, chest obstruction, cardiodynia, megrim, chest stuffiness and cardiodynia caused by agglomeration of phlegm and blood stasis, can reduce vertebral artery resistance obviously and improve cerebral ischemia and cerebral blood circulation, and can be used for disseminated intravascular coagulation, and the absorption of intracerebral hematoma of the cerebral hemorrhage convalescence and sequelae.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and application thereof that contains the treatment cardiovascular and cerebrovascular disease of Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition.The form of Chinese drug that the present invention relates to comprises oral formulations and oral slow (control) release dosage forms thereof such as tablet, capsule and soft capsule, granule, syrup, pellet, microspheres agent, unguentum, sublimed preparation, injection, suppository, cream, spray, patch, micelle, water preparation, liposome, cyclodextrin inclusion compound.With Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and Hirudo are the Chinese medicine preparation blood circulation promoting and blood stasis dispelling of main active, coronary circulation-promoting pain-relieving, be applicable to prevention and treatment meridians Qi deficiency blood stasis type cerebral infarction disease, arteriosclerosis, coronary heart disease, angina pectoris, acute myocardial infarction, ischemia apoplexy, cerebral thrombosis and sequela thereof, the high viscosity of learning, hyperlipidemia, chronic hypertension, the sclerosis of tremulous pulse medicated porridge, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained genus expectorant stasis of blood cohesion person, can significantly reduce the vertebral artery resistance, improve cerebral ischemia and brain blood circulation, also can be used for disseminated inravascular coagulation, the absorption of the intracerebral hematoma of cerebral hemorrhage convalescent period and sequela.
Background technology
Cardiovascular and cerebrovascular disease is commonly encountered diseases, the frequently-occurring disease that threatens human health, rises to human three one of the reasons of dying of illness greatly year by year as the mortality rate of coronary heart disease, angina pectoris, myocardial infarction, has surpassed cancer at its mortality rate of China.And along with China along with the raising of living standards of the people and the aging of population structure, the patient colony of cardiovascular disease is huge day by day.The method and the medicine of integrative therapy cardiovascular and cerebrovascular disease are a lot, Chinese medicine particularly, and because of the curative effect height, toxic and side effects is little, has original advantage.
Radix Salviae Miltiorrhizae another name Radix Salviae Miltiorrhizae, Herba Wedeliae Wallichii, Radix Campylotropis Hirtella (Herba Myrsines Africanae), Arisaema balansae Engl. etc.For Labiatae Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bge), be used as medicine with root.Contain Tanshinone I, II A, II B, iso tanshinone I, II A, cryptotanshinone, different cryptotanshinone, methyltanshinone, hydroxyl TANSHINONES etc., of many uses, be mainly used in stasis-dispelling and pain-killing, promoting blood flow to regulate menstruation, the relieving restlessness etc. of nourishing heart, fine to coronary heart disease, cardiovascular diseases's informal dress curative effect.Radix Salviae Miltiorrhizae extract is in cerebral ischemia reperfusion injury; can reduce ischemic region glutamic acid content; obvious blood flow increasing; reduce leukocyte in the peripheral blood; CD18 and CD11b immune molecule number suppress the inflammatory reaction and the neuronic necrosis of ischemic injuries kitchen range, have the cerebral edema of alleviating; reduce the toxicity of NO, the neuroprotective of effects such as anti peroxidation of lipid after for ischemia has effect preferably.
Semen Ginkgo extrac is the extract of dry Folium Ginkgo, the apricot yellow ketone of argentiferous 〉=24% wherein, Ginkgo total lactones 〉=6%.Cardiovascular and cerebrovascular disease such as treatment coronary heart disease, angina pectoris, scheming infarction, cerebral embolism and respiratory system disease there are significant curative effect, are mainly used in coronary atherosclerotic heart disease.Contained ginkgolide B may pass through to reduce phosphate A2 and hemolytic phosphate esterase active, and antagonism platelet activating factor (PAF) receptor has reduced the platelet height state of activation, has alleviated brain injury.Ginkgolide B also is the neurovirulent main component of antiglutamic acid.The contained ginkgetin of EGb has stronger antioxidation.
Hirudo is the dry body of Hirudinidae animal.Salty in the mouth, hardship, property is flat.Have removing blood stasis, removing blood stasis, the effect of stimulating the menstrual flow.Be used for the blood stasis amenorrhea, diseases such as traumatic injury.China's pharmacology monograph Shennong's Herbal the earliest carries Hirudo " by stagnant blood congestion ".Hirudo contains aminoacid, polypeptide constituents, contains micro-hirudin in the Hirudo live body salivary gland, has blood coagulation resisting function.The water decoction of clinical use dry product Hirudo truly has anticoagulation, shows that other compositions such as polypeptide, protease also have active function.The decocting liquid of Hirudo is live part.The clinical apoplexy that is usually used in, hemiplegia, facial hemiparalysis more is applicable to diseases such as the cerebrology behind the high pressure cerebral hemorrhage is swollen, cerebral thrombosis; And the toxic and side effects of Hirudo is minimum.
The Radix Astragali contains saponins, flavone, aminoacid, polysaccharide and trace element etc.At least contain 3 kinds of saponin in the Radix Astragali, have blood pressure lowering, diuresis, cardiotonic.Also contain osajin, the bright florigen of awns and calycosin etc.Kind of free amino acid surplus containing 20 in the Radix Astragali, wherein more with the content of east, sky amide, canavanine, proline, arginine, aspartic acid R-aminobutyric acid, alanine.Contain multiple polysaccharide in the Radix Astragali immunologic enhancement is arranged.Contain 14 kinds of trace element in the Radix Astragali, wherein higher with ferrum, manganese, selenic content.
The cardiovascular and cerebrovascular disease cause of disease and pathogenesis complexity are the diseases of a deficiency in origin and excess in superficiality.Sick deficiency of qi and blood, the imbalance of YIN and YANG of originally being.Being marked on of disease is turbid in blood stasis, expectorant, wind-fire, QI rising in reverse order etc.Though cardiovascular and cerebrovascular disease sees that disease is different, the blood stasis pathogenesis is identical.The special effect of diagnostic techniques such as MRI and CT in recent years makes medical circle to the blood stasis pathogenesis clear and definite understanding arranged.Thereby clinical treatment cardiovascular and cerebrovascular disease will pay attention to from start to finish cremating congestion in the dissipation cerebral blood vessel.
Deficient, blood stasis, turbid, the normal again reciprocal causation of wind-fire of expectorant affect PD.Gas can not then be transported unable, the hematogenous blockage of blood by handsome blood, stagnates and the stasis of blood.The deficiency of vital energy can not transmitting and distributing the fluids and essence of water and grain, so that the turbid stagnation of the phlegm-damp stasis of blood.Blood stasis obstructing airway, so that the turbid stagnation of expectorant.The turbid mechanism of qi that can block of expectorant follows row, causes qi depression to blood stasis.So blood stasis due to qi deficiency is one of basic pathogenesis of cardiovascular and cerebrovascular disease, also is clinical main cardiovascular and cerebrovascular disease pattern of syndrome.The Therapeutic Principle adopts tonification vigour, activating blood circulation to dissipate blood stasis two method combinations.
Chinese medicine preparation of the present invention adopts the protection to brain neuron of Radix Salviae Miltiorrhizae and Folium Ginkgo, and Radix Astragali QI invigorating, Hirudoization silt match, and QI invigorating is effected a permanent cure, and takes stopgap measures by becoming silted up, make QI invigorating product the power tonify without causing stagnation of change silt mediation; The product of making silt the power of QI invigorating promotion is not lost vigour.Benefiting QI for activating blood circulation and usefulness make unit be so incensed that multiple, and congestion must be dispelled, and guarantees curative effect.
Summary of the invention
The present invention relates to a kind of Chinese medicine preparation and application thereof that contains Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition.Described Chinese medicine preparation is an active component with natural Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and Hirudo or its extract, adds adjuvants such as relevant dispersant, antiseptic.
Pharmaceutical preparation of the present invention can be any pharmaceutically useful dosage form, and the dosage form of Chinese medicine preparation comprises oral formulations and oral slow (control) release dosage forms thereof such as tablet, capsule and soft capsule, granule, syrup, pellet, microspheres agent, unguentum, sublimed preparation, injection, suppository, cream, spray, patch, micelle, water preparation, liposome, cyclodextrin inclusion compound.The effective ingredient high degree of dispersion that can make medicine is in substrate, and is not only rapid-action, the curative effect height, and physicochemical property, pharmacodynamic stability are better, taking convenience, the bioavailability height can cover the bad flavor of smelling of medicine, and the patient is easy to characteristics such as acceptance.
Slow (control) release formulation technology for medicine comprises following aspect: make the little complex of dissolubility, with macromolecular compound generation insoluble chemical compound, be hidden in pharmaceutical pack in the turbid solubility skeleton or in the hydrophilic colloid, with coating blocker coating, be made for capsule or insoluble matrix tablet, make Emulsion, make osmotic pump controlled release tablet.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.Contain following material in the various preparations: oil infiltration agent such as glyceryl monostearate, castor oil hydrogenated, Dormant oils, polysiloxanes, dimethyl polysiloxane etc.; Hydrophilic colloid such as cellulose derivative, arabic gum, sodium alginate, card wave spectrum etc.; Coating blocker such as allyl resin; Other polymer such as polylactic acid, polypropylene, polyvinyl alcohol, ethylene-vinyl acetate copolymer, Polyethylene Glycol, poly-acetic acid, polyglycolic acid, polyamino acid etc.; Antiseptic is one or more in sorbic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, the benzoic acid.The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filleies.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.When being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, the gold-plating guanidine-acetic acid, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, the Fructus Jujubae hydrochlorate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
The Chinese medicine preparation that contains Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition can be made up of following weight proportion: Hirudo 1-10%; Radix Salviae Miltiorrhizae 5-30%; Folium Ginkgo 10-40%; Radix Astragali 3-30%; Dispersant 1-10%; Antiseptic 01-5%.
Chinese medicine preparation of the present invention is to process through extraction or additive method by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, is raw material with this material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, press stockaded village, calcining, grind, sieve, permeate, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the materials that extractum shape is told, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
The extraction of active ingredient of Chinese herbs generally adopts the water body alcohol deposition method refining, filters, and the filtrate vacuum drying was pulverized the 80-100 mesh sieve, got the pressed powder of extract.
The Radix Salviae Miltiorrhizae extraction of active ingredients: add 10 times of amounts, 8 times of amount 80% alcohol reflux secondaries after Radix Notoginseng is pulverized respectively, the time was respectively 2 hours, extracted back recovery ethanol in 2 hours, add water carry out water precipitating after centrifugal D
101Macroporous resin, the resin absorption post washes remove impurity with water, and reuse 80% ethanol carries out desorbing, collects desorbed solution, has reclaimed the exsiccant dried cream of ethanol final vacuum, and dried cream adds 80% ethanol extraction promptly.
Folium Ginkgo extraction of active ingredients: add 10 times of amounts, 8 times of amount 80% alcohol reflux secondaries after dry Folium Ginkgo is pulverized respectively, time was respectively 2 hours, extract the back and reclaimed ethanol, add water and sink centrifugal back resin absorption, wash remove impurity with water, reuse 80% ethanol carries out desorbing, collects desorbed solution, reclaimed the dried cream of ethanol after drying, dried cream adds 90% ethanol extraction promptly.
The extraction of leech active composition: Hirudo is pulverized, and adds 5 times of amount normal saline, fully stirs, and places 10 hours for 5 ℃, and inclining supernatant, extracts 3 times merge extractive liquid, with method.Extracting solution is transferred about pH value to 5 with acetic acid, places 10 hours for 5 ℃, and sucking filtration gets supernatant.Supernatant is transferred pH value to 6 with 20% sodium hydroxide solution, adds ethanol then and makes and contain alcohol and reach 80%, places, and crosses the leaching precipitation, gets the leech active composition with cold drying behind 75% ethanol elution.
Radix Astragali extraction of active ingredients: the Radix Astragali is cut the 1mm decoction pieces, adds 12 times of amounts of water, soaks 5 hours, decoct and extract 3 times, each 2 hours, merge three times decoction liquor, filter, filtrate decompression is concentrated into proportion 1.10, put coldly, add ethanol and make that to contain the alcohol amount be 80%, standing over night, getting supernatant decompression recycling ethanol to concentrated solution does not have the alcohol flavor, and cold drying promptly.
The Chinese medicine preparation blood circulation promoting and blood stasis dispelling of the medicine involved in the present invention and the extract of compositions thereof, coronary circulation-promoting pain-relieving, be applicable to prevention and treatment meridians Qi deficiency blood stasis type cerebral infarction disease, arteriosclerosis, coronary heart disease, angina pectoris, acute myocardial infarction, ischemia apoplexy, cerebral thrombosis and sequela thereof, the high viscosity of learning, hyperlipidemia, chronic hypertension, the sclerosis of tremulous pulse medicated porridge, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained genus expectorant stasis of blood cohesion person, can significantly reduce the vertebral artery resistance, improve cerebral ischemia and brain blood circulation, also can be used for disseminated inravascular coagulation, the absorption of the intracerebral hematoma of cerebral hemorrhage convalescent period and sequela.
Product of the present invention prepares as stated above, and its detailed component is provided by the following example, but protection scope of the present invention is not limited to this.
The specific embodiment
Specify the present invention with embodiment below, these embodiment should not be construed as going up in all senses the present invention are construed as limiting.
Embodiment 1 capsule prescription (1
#)
Radix Salviae Miltiorrhizae extract 500g
Folium Ginkgo extract 1200g
Hirudo extract 500g
Radix Astragali extract 800g
Adjuvant 1000g
Ethylparaben 0.5g
Make 1000 altogether
Preparation method:
Get that above four kinds of extraction of active ingredients things are pulverized, behind the mix homogeneously, add a certain amount of adjuvant mix homogeneously and incapsulate, make 1000 capsules (0.4g/ grain), reinstall in the bottle after aluminum-plastic packaged and seal.
Embodiment 2 tablet formulations (2
#)
Radix Salviae Miltiorrhizae extract 400g
Folium Ginkgo extract 1000g
Hirudo extract 500g
Radix Astragali extract 800g
Right amount of auxiliary materials
Benzoic acid 1.5g
Make 1000 altogether
Get activity extract, behind the adjuvant mix homogeneously, adopt 5% starch slurry system soft material, 18 mesh sieves are granulated, 40 ℃ of dryings, and 16 mesh sieve granulate, behind the adding carboxymethyl starch sodium mix homogeneously, compacting is in flakes.
Embodiment 3 enteric coated tablets prescriptions (3#)
The label prescription:
Radix Salviae Miltiorrhizae extract 600g
Folium Ginkgo extract 800g
Hirudo extract 400g
Radix Astragali extract 1000g
5% starch slurry is an amount of
Starch 100g
Benzoic acid 2.5g
Make 1000 altogether
Coating fluid prescription:
PVAP 10％
Diethyl phthalate 5%
Pulvis Talci 2%
Acetone (1: 1) adds to 100%
Preparation method:
Get activity extract, behind the starch mix homogeneously, adopt 5% starch slurry system soft material, 30 mesh sieves are granulated, 50 ℃ of dryings, and 20 mesh sieve granulate, behind the adding carboxymethyl starch sodium mix homogeneously, the label of compacting.PVAP, diethyl phthalate, Pulvis Talci are joined in proper amount of acetone/alcohol mixeding liquid, and airtight, about 2 hours of magnetic agitation continues and adds the acetone mixed liquor to full dose, continues stir about and gets final product in 1 hour.Above label is carried out coating, notice in the coating process that spray velocity, the flowing velocity of slice, thin piece, the rate of drying of coating solution is inter-adhesive to prevent between the tablet.After coating is finished,, get final product in about 1 hour of 50 ℃ of dryings.
Embodiment 4 enterics drip nine doses of prescriptions (4#)
Prescription:
Radix Salviae Miltiorrhizae extract 400g
Folium Ginkgo extract 700g
Hirudo extract 200g
Radix Astragali extract 800g
Propylene glycol 5g
Make 1000 altogether
Coating fluid prescription:
Eudragit?R 15％
Citric acid three ester 6%
Glycerol 5%
Pulvis Talci 3%
Ethanol adds to 100%
Preparation method:
After stearic acid three esters of getting recipe quantity are heated to fusion, treat that it is cooled to about 50 ℃, add activity extract, stirring, regulate the water dropper size system of dripping, is coolant with dimethicone or liquid paraffin, chilling temperature is about-10 ℃, selects ball, is drying to obtain.Eudragit R, citric acid three ester added in 80% the alcoholic solution and dissolve, stir about 3 hours at a slow speed under magnetic stirring apparatus makes it dissolving fully, adds surplus ethanol and Pulvis Talci, glycerol, and continuing to stir is to get final product in 1 hour.Drop pill is placed coating pan, and control inlet temperature and hydrojet speed prevent the drop pill adhesion, and coating is carried out smoothly.After coating finishes, dry getting final product.
Embodiment 5 granules prescription (5
#)
Radix Salviae Miltiorrhizae extract 50g
Folium Ginkgo extract 150g
Hirudo extract 20g
Radix Astragali extract 100g
Right amount of auxiliary materials
Ethylparaben 2.5g
Make 1000 bags altogether.
After getting above two kinds of active component pulverizing, mix homogeneously, add a certain amount of adjuvant mix homogeneously, make soft material in right amount with ethanol, the system granule, cold drying, granulate gets granule 1000g, is distributed into bag (a 1g/ bag).
Embodiment 6: to the pharmacodynamics test of rat myocardium block
Rat is divided into 7 groups at random by body weight, 10 every group, promptly 1
#-5
#Sample sets, positive control drug Piracetam Capsule group (50mg/kg), model control group (waiting the capacity solvent).Medicine is pressed dosage, is made into suitable concentration respectively with Sodium Tvlose, and gastric infusion is irritated stomach every day 2 times.Model control group is irritated the isometric Sodium Tvlose solution of stomach.Continuous irrigation stomach 4 days after the anesthesia, practices artificial respiration the animal endotracheal intubation.Go out to cut off the 3rd rib in left border of sternum 0.5cm and open breast, open pericardium after exposing the thoracic cavity, with silk thread intersection ligation left anterior descending coronary artery below pulmonary artery and left auricle lower edge, show that with left chamber antetheca cyanosis or bluish violet and electrocardiogram moving on the ST section more than the 0.2mV is that ligation successfully indicates, heart is put back in the thoracic cavity, sewed up thoracic wall.
Ventricle is got blood 3ml behind coronary ligation 3h.Win rat heart then and send new intracavity hematocele, inhale the branch that anhydrates, reject non-cardiac muscular tissue, wipe out atrium and right ventricle, stay left ventricle and weigh with normal saline flushing and with filter paper.Ventricle is cut into myocardium sheet, puts into buffer, dyeing, infarcted region is not peony, and infarcted region is white in color, and separates in the myocardium sheet infarcted region and weighs, and calculating infarcted region (weight in wet base), to account for left ventricle (weight in wet base) percentage ratio be the heart infarction scope.As a result, model control group has tangible ischemia phenomenon, and infarction size accounts for 33.1%, 1 of left ventricle
#-5
#Sample sets and Naoxuekang capsule for curing cerebrovascular disease group all can be observed the effect that significantly resists myocardial ischemia, and myocardial infarct size obviously dwindles (P＜0.01),
Influence to myocardial infarct size behind the rat coronary ligation
Group heart infarction scope (%, heart infarction district/left chamber weight in wet base)
1
# 10.2±1.3
2
# 11.6±1.5
3
# 11.4±1.1
4
# 10.8±1.5
5
# 9.4±1.4
Model control group 33.1 ± 2.3
Naoxuekang capsule for curing cerebrovascular disease group 19.2 ± 1.2
Annotate: compare P＜0.05 with model control group
Embodiment 10: to the pharmacodynamics test of rat myocardium block
Select the Wistar rat, male and female half and half, body weight 220-280 gram is divided into 7 groups at random, 12 every group, irritates stomach in preceding 24 hours and 1 hour respectively at test and awards 1
#-5
#Sample by 3g/kg (being equivalent to people's equivalent) and etc. the dosage NIAOXUEKANG, and the matched group tap water, irritate stomach volume 0.5ml/100g, do thrombotic inhibitory action test.
Rat test of pesticide effectiveness result
Organize the wet amount of routine dosage (g/kg) thrombosis (mg) suppression ratio (100%)
Matched group/39 ± 70
1
# 3.0 11±3# 74
2
# 3.0 12±4# 71
3
# 3.0 10±3# 78
4
# 3.0 11±1# 76
5
# 3.0 12±3# 77
NIAOXUEKANG 0.3 17 ± 3# 56
Annotate relatively P＜0.01 of # and matched group
Experimental result shows 1
#-5
#The inhibitory action that sample forms rat suppository all significantly is better than the NIAOXUEKANG of corresponding dosage.
Embodiment 7: the toxicological study result
Acute toxicity test: it is 50g/kg (medicine/body weight) that mice once gavages maximum dose, is 250 times of clinical maximum consumption per day, illustrates that it is safe and reliable that said preparation is intended consumption clinically.
Long term toxicity test: respectively to nine weeks of rat oral gavage, the result shows: soft capsule test group platelet count obviously reduces with difference prescription soft capsule 0.5,1.0, three dosage of 4.0g/kg and normal saline, and conventional other index of rat serum is not had obvious effect; Administration group serum biochemistry index is starkly lower than matched group, and the administration treated animal heart, liver weight coefficient are lower than matched group, but can recover after two weeks of drug withdrawal, all the other internal organs spleens, lung, kidney device weight coefficient and the equal no significant difference of matched group; The pathological examination animal heart, liver, spleen, lung, kidney are not found obviously unusual.
Those skilled in the art's book according to the above description carry out various modifications and change to compositions and method.All such modifications in the appended claims scope all are included in the scope of the present invention.
Claims (5)
1. the present invention relates to a kind of Chinese medicine preparation and application thereof that contains the treatment cardiovascular and cerebrovascular disease of Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition.
2. described dosage form comprises oral formulations and oral slow (control) release dosage form thereof of tablet, capsule and soft capsule, granule, syrup, pellet, microspheres agent, unguentum, sublimed preparation, injection, suppository, cream, spray, patch, micelle, water preparation, liposome, cyclodextrin inclusion compound.
3. aforementioned claim 1 contains following material to the desired medicine of claim 2: oil infiltration agent such as glyceryl monostearate, castor oil hydrogenated, Dormant oils, polysiloxanes, dimethyl polysiloxane; Hydrophilic colloid such as cellulose derivative, arabic gum, sodium alginate, card wave spectrum etc.; Coating blocker such as allyl resin; Other polymer such as polylactic acid, polypropylene, polyvinyl alcohol, ethylene-vinyl acetate copolymer), Polyethylene Glycol, poly-acetic acid, polyglycolic acid, polyamino acid; Antiseptic is one or more in sorbic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, the benzoic acid.
4. aforementioned claim 1 to the desired pharmaceutical composition of claim 3 is made up of following weight proportion: Hirudo 1-10%; Radix Salviae Miltiorrhizae 5-30%; Folium Ginkgo 10-40%; Radix Astragali 3-30%; Dispersant 1-10%; Antiseptic 0.1-5%.
5. weigh aforementioned claim 1 to the desired pharmaceutical composition blood circulation promoting and blood stasis dispelling of claim 4, coronary circulation-promoting pain-relieving, be applicable to prevention and treatment meridians Qi deficiency blood stasis type cerebral infarction disease, arteriosclerosis, coronary heart disease, angina pectoris, acute myocardial infarction, ischemia apoplexy, cerebral thrombosis and sequela thereof, the high viscosity of learning, hyperlipidemia, chronic hypertension, the sclerosis of tremulous pulse medicated porridge, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained genus expectorant stasis of blood cohesion person, can significantly reduce the vertebral artery resistance, improve cerebral ischemia and brain blood circulation, also can be used for disseminated inravascular coagulation, the absorption of the intracerebral hematoma of cerebral hemorrhage convalescent period and sequela.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910131887A CN101856389A (en) | 2009-04-09 | 2009-04-09 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910131887A CN101856389A (en) | 2009-04-09 | 2009-04-09 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101856389A true CN101856389A (en) | 2010-10-13 |
Family
ID=42942693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910131887A Pending CN101856389A (en) | 2009-04-09 | 2009-04-09 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101856389A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327145A (en) * | 2015-11-28 | 2016-02-17 | 王文福 | Composition for treating hypertensive cerebral hemorrhage and preparation method thereof |
| CN109568500A (en) * | 2018-12-13 | 2019-04-05 | 张辉 | A kind of Chinese medicine and its preparation process prevented or treat hypertensive stroke |
| US11168287B2 (en) | 2016-05-26 | 2021-11-09 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| US11737458B2 (en) | 2015-04-01 | 2023-08-29 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
| CN117224590A (en) * | 2023-09-27 | 2023-12-15 | 哈尔滨珍宝制药有限公司 | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
| CN117643605A (en) * | 2023-09-27 | 2024-03-05 | 哈尔滨珍宝制药有限公司 | Traditional Chinese medicine composition for treating coronary heart disease with syndrome of qi deficiency and blood stasis |
| US12037497B2 (en) | 2016-01-28 | 2024-07-16 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition against DNA viruses and method of inhibiting the adherence of DNA viruses to a surface |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985965A (en) * | 2006-07-23 | 2007-06-27 | 李锡尧 | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method |
| CN101085024A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and ginkgo leaves and its preparation |
-
2009
- 2009-04-09 CN CN200910131887A patent/CN101856389A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085024A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and ginkgo leaves and its preparation |
| CN1985965A (en) * | 2006-07-23 | 2007-06-27 | 李锡尧 | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method |
Non-Patent Citations (1)
| Title |
|---|
| 王佟等: "水蛭胶囊配合复方丹参及黄芪治疗不稳定型心绞痛疗效观察", 《医学研究杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11737458B2 (en) | 2015-04-01 | 2023-08-29 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
| CN105327145A (en) * | 2015-11-28 | 2016-02-17 | 王文福 | Composition for treating hypertensive cerebral hemorrhage and preparation method thereof |
| US12037497B2 (en) | 2016-01-28 | 2024-07-16 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition against DNA viruses and method of inhibiting the adherence of DNA viruses to a surface |
| US11168287B2 (en) | 2016-05-26 | 2021-11-09 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| CN109568500A (en) * | 2018-12-13 | 2019-04-05 | 张辉 | A kind of Chinese medicine and its preparation process prevented or treat hypertensive stroke |
| CN117224590A (en) * | 2023-09-27 | 2023-12-15 | 哈尔滨珍宝制药有限公司 | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
| CN117643605A (en) * | 2023-09-27 | 2024-03-05 | 哈尔滨珍宝制药有限公司 | Traditional Chinese medicine composition for treating coronary heart disease with syndrome of qi deficiency and blood stasis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101856389A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN103623341A (en) | Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension | |
| CN105267943A (en) | Lumbricus bioactive small peptide effective part composition | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN104173264A (en) | Rose essence oil hydrogel patch and preparation method thereof | |
| CN104758806A (en) | Decocted extract for treating coronary heart disease and preparation method thereof | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN109731074A (en) | A kind of for oral administration and external application suit and preparation method thereof for alleviating asthenopia and xerophthalmia | |
| CN102293923B (en) | Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis | |
| CN103830436A (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102657795A (en) | Traditional Chinese medicine preparation for promoting postoperative incision healing | |
| CN103182008A (en) | Preparation method for traditional Chinese medicine used for stabilizing and reducing blood pressure | |
| CN105687522A (en) | Pharmaceutical composition with chloasma removing function and preparation method thereof | |
| CN1180821C (en) | Medicine for treating cerebral thrombus and its prepn | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN1887324B (en) | Chinese medicine composition for treating liver and kidney defect, and its preparation process and analysis method | |
| CN103494916B (en) | Traditional Chinese medicine composition with effect of reducing blood sugar, as well as preparation method and application thereof | |
| CN101313989B (en) | Chinese medicinal composition for treating coronary disease, stenocardia | |
| CN1321484A (en) | Medicine for curing coronary heart disease with hypertension and its preparation process | |
| CN103431387B (en) | Whitening and freckle-removing traditional Chinese medicine composition and preparation process thereof | |
| CN118303621B (en) | Composition for improving female menopausal symptoms and preparation method | |
| CN1229122C (en) | Combination of Chinese herbal medicine for treating high blood pressure | |
| CN100348227C (en) | Oral medicine preparation for treating apoplexy and sequela | |
| CN104147186A (en) | Rose essential oil hydrogel plaster and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101013 |